Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from BioNTech SE ( (BNTX) ).
On September 8, 2025, BioNTech SE and Bristol Myers Squibb presented interim data from a Phase 2 trial evaluating pumitamig, a bispecific antibody, in patients with extensive-stage small cell lung cancer. The data showed promising antitumor activity, with a 76.3% confirmed objective response rate and a 100% disease control rate, suggesting potential for pumitamig to become a new standard of care in this aggressive cancer type. The trial’s results are being used to inform a global Phase 3 trial, and pumitamig has received Orphan Drug designation from the FDA.
The most recent analyst rating on (BNTX) stock is a Hold with a $120.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech SE’s overall stock score is driven by its strong balance sheet and positive earnings call sentiment, despite profitability and cash flow challenges. Technical indicators show a positive short-term trend, but valuation is impacted by negative earnings. Strategic collaborations and a strong cash position provide a positive outlook, but operational improvements are necessary for long-term stability.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a global biopharmaceutical company specializing in the development of next-generation immunotherapies and vaccines, with a focus on oncology and infectious diseases.
Average Trading Volume: 735,145
Technical Sentiment Signal: Buy
Current Market Cap: $27.04B
For a thorough assessment of BNTX stock, go to TipRanks’ Stock Analysis page.